Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
It is very uncertain whether inulin and oligofructose 15 g changes withdrawals due to adverse events (9 weeks) compared with inulin and oligofructose 7.5 g daily (very low certainty).
1 finding from 1 review
Adverse events (spotting at 3 and 6 months) · women with uterine fibroids
1 finding from 1 review
Overall local/injection site adverse events · 9‐ to 14‐year‐old females and males
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall local/injection site adverse events · 9‐ to 15‐year‐old females
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: paraesthesia ‐ not reported · patients undergoing lumbar punctures with traumatic needles (Quincke, Greene, Hingson Ferguson, Lutz, Brace, Rovenstine, Lemmon)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events Falls while switching glasses · Older people living in the community
Assistive technology for vision improvement interventions showed no clear difference in adverse events Falls while switching glasses compared with usual care or attention control (low certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
It is very uncertain whether casirivimab/imdevimab changes adverse events: grade 3 to 4 within 6 months compared with placebo (very low certainty).
2 findings from 1 review
Grades 3 and 4 adverse events · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events associated with RIC treatment · people at risk for ischaemic stroke
RIC may leads to higher adverse events associated with RIC treatment compared with non‐RIC (low certainty).
1 finding from 1 review
Adverse events (e.g. ulcers, tooth staining) · Children and adolescents below 18 years at study start (included studies: children from birth to 15 years), with mixed, permanent or…
1 finding from 1 review
Infant Grade 3/4 Severe Adverse Events · HIV‐infected mothers and their breastfeeding infants
An extended ZDV/3TC/LPV/r regimen administered to mothers showed no clear difference in infants with Grade 3/4 Severe Adverse Events compared with an extended ZDV/3TC/ABC administered to mothers (low certainty).
1 finding from 1 review
Intervention not reported
Incidence of gastrointestinal adverse events · children (age < 18 years) susceptible to acute respiratory tract infections (ARTIs)
1 finding from 1 review
Adverse events assessed during catheter dwell · people with arterial catheter dressing and securement
It is very uncertain whether bordered polyurethane changes adverse events assessed during catheter dwell compared with standard polyurethane (very low certainty).
1 finding from 1 review
Any adverse events (excluding major bleeding) · people with cerebral small vessel disease and no dementia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tolerability ‐ total number of adverse events · adults with long‐term physical conditions (18 years or older)
1 finding from 1 review
Tolerability ‐ total number of adverse events · adults with long‐term physical conditions (18 years or older)
1 finding from 1 review
Adverse events: severe adverse events (total) · children (aged 1 to 12 years) with CF and a newly isolated PA infection
Summary of findings: cycled showed no clear difference in adverse events: severe adverse events (total) compared with culture‐based antibiotic therapy (moderate certainty).
1 finding from 1 review
Serious adverse events assessed using ICH‐GCP
It is very uncertain whether L‐ornithine L aspartate changes serious adverse events assessed using ICH‐GCP compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Adverse events associated with transfusion · People with a haematological disorder
1 finding from 1 review
Adverse events requiring hospitalisation (SAE) · Neonates and caregivers
It is very uncertain whether four per cent chlorhexidine + hand hygiene promotion changes adverse events requiring hospitalisation (SAE) compared with usual care (very low certainty).
1 finding from 1 review